KarXT is a safe and effective novel antipsychotic for patients with schizophrenia
1. Patients in the KarXT (xanomeline–trospium) group reported a significant reduction in Positive and Negative Syndrome Scale (PANSS) score compared ...
Tag: antipsychotics
Early non-response is a predictor of later non-response to antipsychotics in schizophrenia
1. For patients with schizophrenia, symptomatic response to antipsychotic medication at 2 and 4 weeks after initiation can appropriately predict ...
Antipsychotic medication analysis among older adults with infection-related delirium
Antipsychotic Medication Use Among Older Adults Following Infection-Related Hospitalization 1. In patients with newly initiated antipsychotic medications following infection-related hospitalization, ...
Ecopipam reduces tics in children with Tourette syndrome
1. In a phase 2 trial of patients with Tourette syndrome, ecopipam, a selective dopamine receptor antagonist, was associated with a ...
Haloperidol does not improve outcomes at 90 days in ICU patients with delirium
1. In intensive care unit (ICU) patients with delirium, haloperidol treatment did not improve the number of days alive and ...
Adjuvant antipsychotic use in children treated for depression may be associated with movement disorders
1. This cohort study concluded that the concomitant use of antipsychotic and antidepressant medications in children was associated with movement ...
Prenatal exposure to antipsychotic medications not associated with increased risk of neurodevelopmental disorders in offspring
1. Prenatal exposure to commonly prescribed antipsychotic medications did not appear to meaningfully increase risk of neurodevelopmental disorders in offspring. ...
Anti-psychotic medication use during pregnancy not associated with attention-deficit/hyperactivity disorder, autism spectrum disorder or small for gestational age in children
1. Children of mothers who were exposed to anti-psychotics during pregnancy, compared to those never exposed, did not have an ...
#VisualAbstract: A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
1. An oral compound, SEP-363856 was shown to significantly reduce the total score of the Positive and Negative Symptom Scale ...
Quick Take: Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs. other oral second-generation antipsychotics
Patients with schizophrenia that do not respond to 2 or more antipsychotics are considered to have treatment-resistant disease. In these ...